Methodological framework proposes updated criteria for evaluating subgroup analyses in clinical trials, highlighting improved differentiation between real and spurious effects.
How can we tell the difference between spurious and real subgroup effects? This article identifies new criteria and proposes a checklist for judging the credibility of subgroup analyses
No takes yet. Share an insight, caveat, or question.
Sun et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: